Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
In development
Reference number: GID-TA10905
Expected publication date: TBC
As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during early June 2023.